Skip to main content
. 2018 May 1;9(33):23091–23101. doi: 10.18632/oncotarget.25214

Figure 6. TNFSF10 (TRAIL) expression levels associated with prognosis for patients with metastatic RCC.

Figure 6

To determine TNFSF10 (TRAIL) expression levels, clinical samples from patients with metastatic RCCs were analyzed by qRT-PCR with GAPDH normalization (left panel). The black line indicates the average value of TNFSF10 expression. The RCC patients were categorized in high or low TNFSF10 expression groups based on the average value. Kaplan-Meier survival curves for TNFSF10 in patients with metastatic RCC (right panel). The high TNFSF10 group was associated with significantly shorter survival periods compared with the low TNFSF10 group after chemotherapy (log-rank test, p = 0.015).